Product Use Citations
-
Mologni L, et al. The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition.
J Cancer. 2017, 8(1):140-145.
Vandetanib (ZD6474) purchased from Selleck.
-
Ji C, et al. Gremlin inhibits UV-induced skin cell damages via activating VEGFR2-Nrf2 signaling.
Oncotarget. 2016, 7(51):84748-84757.
Vandetanib (ZD6474) purchased from Selleck.
-
Fischer A, et al. Optogenetic clustering of CNK1 reveals mechanistic insights in RAF and AKT signalling controlling cell fate decisions.
Sci Rep. 2016, 6:38155.
AT7867 purchased from Selleck.
-
Xie S, et al. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
Acta Pharmacol Sin. 2016, 37(11):1481-1489.
Flavopiridol HCl purchased from Selleck.
-
Nishioka H, et al. BMS-708163 and Nilotinib restore synaptic dysfunction in human embryonic stem cell-derived Alzheimer's disease models.
Sci Rep. 2016, 6:33427.
Avagacestat (BMS-708163) purchased from Selleck.
-
Jin JX, et al. The HDAC Inhibitor LAQ824 Enhances Epigenetic Reprogramming and In Vitro Development of Porcine SCNT Embryos.
Cell Physiol Biochem. 2017, 41(3):1255-1266.
Dacinostat (LAQ824) purchased from Selleck.
-
Shimada Y, et al. An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma.
Oncologist. 2017, 22(2):158-164.
Alectinib (CH5424802) purchased from Selleck.
-
Hsieh MS, et al. The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma.
Oncotarget. 2016, 7(24):36956-36970.
AC480 (BMS-599626) purchased from Selleck.
-
Yadav SS, et al. Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications.
Transl Oncol. 2017, 10(3):357-366.
Dovitinib (TKI-258) Dilactic Acid purchased from Selleck.
-
van de Ven AL, et al. Nanoformulation of Olaparib amplifies PARP inhibition and sensitizes PTEN/TP53-deficient prostate cancer to radiation.
Mol Cancer Ther. 2017, 10.1158/1535-7163.MCT-16-0740.
Olaparib (AZD2281, Ku-0059436) purchased from Selleck.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
AllPage:
Page:
